Kiromic BioPharma, Inc.
KRBP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | -0.57 | 1.38 |
| FCF Yield | -84.49% | -74.81% | -32.33% | -4.24% |
| EV / EBITDA | -1.55 | -2.51 | -2.99 | -19.40 |
| Quality | ||||
| ROIC | 216.34% | -310.50% | -855.80% | -92.90% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.72 | 1.01 | 0.68 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 7.50% | 25.13% | -28.85% | -192.93% |
| Safety | ||||
| Net Debt / EBITDA | -0.56 | -0.76 | -0.27 | 0.97 |
| Interest Coverage | 6.39 | 10.77 | -186.87 | -2,109.48 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -278.85 | -1,290.12 | -1,720.35 |